Alexion Pharmaceuticals (NASDAQ:ALXN) released its earnings results on Thursday. The biopharmaceutical company reported $3.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.32 by $0.79, MarketWatch Earnings reports. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%. The firm had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.27 billion. Alexion Pharmaceuticals updated its FY 2020
Pre-Market guidance to 10.65-10.95 EPS.
Shares of ALXN stock opened at $102.49 on Friday. The stock’s fifty day simple moving average is $110.49 and its 200 day simple moving average is $102.94. Alexion Pharmaceuticals has a one year low of $72.67 and a one year high of $125.52. The firm has a market cap of $22.63 billion, a price-to-earnings ratio of 27.40, a P/E/G ratio of 0.81 and a beta of 1.46. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.79 and a quick ratio of 3.82.
A number of research firms have recently commented on ALXN. Cantor Fitzgerald began coverage on Alexion Pharmaceuticals in a research note on Monday, April 27th. They issued a “neutral” rating and a $121.00 price objective on the stock. William Blair downgraded Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. JPMorgan Chase & Co. reduced their price objective on Alexion Pharmaceuticals from $168.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 28th. Finally, Credit Suisse Group upped their target price on shares of Alexion Pharmaceuticals from $142.00 to $147.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $143.17.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Story: What are different types of coverage ratios?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.